Imatinib, a first line chemotherapeutic treatment for chronic myeloid leukemia, is a selective tyrosine kinase inhibitor of PDGF signaling, among other pathways including FLT3, Lck and MAPK cascades [180]. The gene discussed is LCK; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.